Genmab
GMAB
293 hedge funds and large institutions have $2.26B invested in Genmab in 2025 Q4 according to their latest regulatory filings, with 77 funds opening new positions, 123 increasing their positions, 53 reducing their positions, and 29 closing their positions.
166% more first-time investments, than exits
New positions opened: 77 | Existing positions closed: 29
132% more repeat investments, than reductions
Existing positions increased: 123 | Existing positions reduced: 53
31% more call options, than puts
Call options by funds: $3.33M | Put options by funds: $2.54M
16% more capital invested
Capital invested by funds: $1.94B → $2.26B (+$313M)
16% more funds holding
Funds holding: 253 → 293 (+40)
1.77% more ownership
Funds ownership: 9.64% → 11.4% (+1.8%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OAG
Orbis Allan Gray
Hamilton,
Bermuda
|
+$104M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
+$100M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$41.6M |
| 4 |
BlackRock
New York
|
+$35.6M |
| 5 |
Pictet Asset Management
Carouge,
Switzerland
|
+$34.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$53M |
| 2 |
Two Sigma Advisers
New York
|
-$34.1M |
| 3 |
Two Sigma Investments
New York
|
-$15.4M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$14.8M |
| 5 |
BGIM
Brandywine Global Investment Management
Philadelphia,
Pennsylvania
|
-$11.9M |
GMAB Hedge Fund Activity: Q4 2025 in Review
293 of the 8,263 institutional investors tracked by Wall St. Rank reported a position in Genmab (GMAB) for Q4 2025, worth a combined $2.26B — up 16% from $1.94B a quarter earlier.
Buyers outnumbered sellers: 77 funds opened new GMAB positions and 29 closed out — a net gain of 48 holders — while 123 added to existing stakes and 53 trimmed.
The largest buyer was Orbis Allan Gray, adding an estimated $104M. The largest seller was Ikarian Capital, exiting entirely with an estimated $53M sold.
- 293 institutional investors held Genmab (GMAB) as of Q4 2025, up from 253 in Q3 2025.
- Funds reported $2.26B of Genmab stock for Q4 2025, up 16% quarter-over-quarter.
- 77 funds opened new Genmab positions in Q4 2025 and 29 closed out, a net change of +48 holders.
- The largest Genmab buyer in Q4 2025 was Orbis Allan Gray, an estimated $104M added.
- The largest Genmab seller in Q4 2025 was Ikarian Capital, an estimated $53M sold.
Based on aggregated 13F filings for Q4 2025.